Physician Assistant Program year 2025 Reported 2022–2025 Source: CMS Open Payments, 2026 publication

Christa Cooper

Physician Assistant Chicago, IL Physician Assistant

NPI 1831440254 CMS profile 10620574

259 E Erie St Ste 1900, Chicago, IL 60611

Open in the dashboard

General payments

$35,786

84 records reported · program years 2022–2025

Research payments

$0

Paid to them · None reported · program years 2022–2025

Ownership & investment interest

$0

None reported

Through program year 2025, Christa Cooper of Chicago, IL is reported in the CMS Open Payments database as having received $35,786 across 84 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 99th percentile of Physician Assistant profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

4 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $30,998 62
2024 General $603 6
2023 General $3,898 14
2022 General $286 2

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Christa Cooper
  • Physician Assistant median
  • Middle half of Physician Assistant
  • National median

In program year 2025, general payments to Christa Cooper were reported at $30,998. Among 68,903 Physician Assistant profiles paid that year, the median was $184 and the middle half received between $57 and $620.

Show as a table
Year Christa Cooper Physician Assistant median Middle half National median
2019 $0 $34 $17–$122 $163
2020 $0 $33 $16–$78 $114
2021 $0 $132 $37–$438 $132
2022 $286 $155 $48–$522 $149
2023 $3,898 $167 $52–$557 $160
2024 $603 $178 $55–$600 $164
2025 $30,998 $184 $57–$620 $169

Breakdown

Who paid General payments · program years 2022–2025
  1. Neurocrine Biosciences, Inc. $12,967 19 payments
  2. Teva Pharmaceuticals USA, Inc. $11,844 17 payments
  3. Abbott Laboratories $9,300 40 payments
  4. ACADIA Pharmaceuticals Inc $998 2 payments
  5. US WorldMeds, LLC $500 2 payments
  6. Boston Scientific Corporation $111 1 payment
  7. Medtronic, Inc. $49 2 payments
  8. Cala Health, Inc. $17 1 payment

Every payment, record by record

What the payments were for General payments · program years 2022–2025
  1. Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program $14,460 11 payments
  2. Consulting Fee $10,165 8 payments
  3. Travel and Lodging $6,508 27 payments
  4. Compensation for serving as faculty or as a speaker for a medical education program $2,675 3 payments
  5. Food and Beverage $1,878 34 payments
  6. Education $100 1 payment
Products named General payments · program years 2022–2025
  1. INGREZZA $12,967 19 payments
  2. Austedo XR $11,744 16 payments
  3. INFINITY Structural Heart $5,315 19 payments
  4. INFINITY Neuromodulation $3,450 16 payments
  5. NUPLAZID $998 2 payments
  6. PROCLAIM Structural Heart $414 4 payments
  7. PROCLAIM Structural Heart $121 1 payment
  8. General - DBS $111 1 payment
  9. Ongentys $100 1 payment
  10. SenSight $29 1 payment
  11. Other $38 2 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 17 drugs

Part D claims

536

Median for Physician Assistant: 241

Drug cost

$731,551

Median for Physician Assistant: $4,110

Branded share of claims

66.8%

Median for Physician Assistant: 19.6%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Austedo Xr Deutetrabenazine Brand 37 $313,744
Austedo Deutetrabenazine Brand 23 $254,204
Nuplazid Pimavanserin Tartrate Brand 14 $69,625
Inbrija Levodopa Brand 19 $64,981
Neupro Rotigotine Brand 15 $12,303
Entacapone Generic 23 $4,912
Carbidopa-Levodopa Carbidopa/Levodopa Brand 123 $4,512
Amantadine Amantadine Hcl Brand 71 $2,869
Carbidopa-Levodopa Er Carbidopa/Levodopa Brand 45 $1,700
Fluoxetine Hcl Generic 15 $623

The 10 drugs with the highest cost, of 17 counted.

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 114,276 Part D prescribers listed as Physician Assistant; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 18 billing codes

Paid by Medicare

$14,651

Medicare's payments for the services billed

Medicare patients

119

Average age 70

Services billed

453

53 women, 66 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
High blood pressure 56%
Depression 44%
Arthritis 43%
Alzheimer's or dementia 28%
Ischemic heart disease 22%
Diabetes 20%
Chronic kidney disease 15%
Cancer 13%

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Records

84 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Physician Assistant in Illinois

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record